IP Library Granted Patent US 9,751,953
Granted Patent B2
US 9,751,953 · App. 13/971,475 · Granted Sep 5, 2017

Antibodies to risperidone haptens and use thereof

Inventors: Eric Hryhorenko (Hilton, NY); Banumathi Sankaran (Lexington, MA); Thomas R. DeCory (Pittsford, NY); Theresa Tubbs (Rochester, NY); Linda Colt (Rochester, NY); Maarten Vliegen (Rijkevorsel, BE); Pieter Rik Haspeslagh (Halen, BE)
Assignee: JANSSEN PHARMACEUTICA NV
C07K16/44G01N33/94G01N2800/302
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,751,953
App. No.
13/971,475
Granted
Sep 5, 2017
Kind
B2
Abstract

Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Claims (32)

1. A method of producing an antibody which binds to risperidone, the method comprising:

(i) selecting a host for antibody production; and

(ii) inoculating the host with a conjugate of a compound of Formula I and an immunogenic carrier, wherein the host produces the antibody which binds to risperidone,

Formula I:

wherein:

R 1 is H, or OH;

R 2 is

or O(CH 2 ) r NHC(O)(CH 2 ) m CO 2 H;

wherein:

r is 1, 2, 3, 4, or 5;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

2. The method of claim 1 , wherein the antibody is an antibody binding fragment which is selected from the group of fragments consisting of Fv, F(ab′), F(ab′)2, scFv, minibody and diabody fragments.

3. The method of claim 1 , wherein the antibody is a monoclonal antibody.

4. The method of claim 1 , wherein the immunogenic carrier is a protein.

5. The method of claim 4 , wherein the protein is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

6. A method of producing a hybridoma cell line, which produces a monoclonal antibody which binds to risperidone, the method comprising:

(i) selecting a host for antibody production;

(ii) inoculating the host with a conjugate of a compound of Formula I and an immunogenic carrier;

(iii) fusing a cell line from said inoculated host, wherein the cell line produces antibodies that bind to risperidone, with a continuously dividing cell to create a fused cell, which produces a monoclonal antibody which binds to risperidone; and

(iv) cloning the fused cell so as to obtain a hybridoma cell line,

Formula I:

wherein:

R 1 is H, or OH;

R 2 is

or O(CH 2 ) r NHC(O)(CH 2 ) m CO 2 H;

wherein:

r is 1, 2, 3, 4, or 5;

m is 1, 2, 3, 4, or 5; and

n is 1, 2, 3, 4, or 5.

7. The method of claim 6 , wherein the immunogenic carrier is a protein.

8. The method of claim 7 , wherein the protein is keyhole limpet hemocyanin, bovine thyroglobulin, or ovalbumin.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2016
From: ORTHO-CLINICAL DIAGNOSTICS, INC.
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 039615/0175 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2014
From: HRYHORENKO, ERIC; SANKARAN, BANUMATHI; DECORY, THOMAS R.; TUBBS, THERESA; COLT, LINDA
To: ORTHO-CLINICAL DIAGNOSTICS, INC.
Reel/Frame 032435/0812 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2014
From: VLIEGEN, MAARTEN; HASPESLAGH, PIETER RIK
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 032435/0857 →
Continuity (2)
Provisional Application 61691615 · Aug 21, 2012
Related Publication 20140057301A1 · Feb 27, 2014